Association of the TNF-α G-308A polymorphism with TNF-inhibitor response in sarcoidosis

European Respiratory Journal

Volumn 43, Issue 6, 2014, Pages 1730-1739

  Wijnen, Petal A ^a   Cremers, Johanna P ^b   Nelemans, Patty J ^c   Erckens, Roel J ^a   Hoitsma, Elske ^d   Jansen, Tim L ^e   Bekers, Otto ^a   Drent, Marjolein ^b,c  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b GELDERSE VALLEI HOSPITAL   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d Dept of Ophthalmology Maastricht University Medical Centre ^*  (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; DIPEPTIDYL CARBOXYPEPTIDASE; INFLIXIMAB; INTERLEUKIN 2 RECEPTOR; METHOTREXATE; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; DNA POLYMORPHISM; DRUG EFFICACY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; GENE FREQUENCY; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HERPES ZOSTER; HUMAN; LUNG SARCOIDOSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SARCOIDOSIS; SEPSIS; SKIN DEFECT; SMALL FIBER NEUROPATHY; TNF ALPHA GENE; UVEITIS; ALLELE; ANTAGONISTS AND INHIBITORS; COMPLICATION; GENETIC POLYMORPHISM; GENETICS; INFLAMMATION; MIDDLE AGED; NEUROLOGIC DISEASE; PATHOLOGY; PROBABILITY; THORAX RADIOGRAPHY; TREATMENT OUTCOME;

ADULT; ALLELES; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; GENOTYPE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; POLYMORPHISM, GENETIC; PROBABILITY; RADIOGRAPHY, THORACIC; SARCOIDOSIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS;

EID: 84897519077     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00169413     Document Type: Article

References (38)

1. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999; 160: 736-755.
2. Iannuzzi MC, Fontana JR. Sarcoidosis: clinical presentation, immunopathogenesis, and therapeutics. JAMA 2011; 305: 391-399.
3. Fehrenbach H, Zissel G, Goldmann T, et al. Alveolar macrophages are the main source for tumour necrosis factor-α in patients with sarcoidosis. Eur Respir J 2003; 21: 421-428. (Pubitemid 36336199)
4. Baughman RP, Costabel U, du Bois RM. Treatment of sarcoidosis. Clin Chest Med 2008; 29: 533-548. (Pubitemid 351784486)
5. Baughman RP, Nunes H, Sweiss NJ, et al. Established and experimental medical therapy of pulmonary sarcoidosis. Eur Respir J 2013; 41: 1424-1438.
6. Grutters JC, van den Bosch JM. Corticosteroid treatment in sarcoidosis. Eur Respir J 2006; 28: 627-636. (Pubitemid 44794680)
7. Baughman RP. Pulmonary sarcoidosis. Clin Chest Med 2004; 25: 521-530. (Pubitemid 39149799)
8. Paramothayan S, Lasserson T. Treatments for pulmonary sarcoidosis. Respir Med 2008; 102: 1-9. (Pubitemid 350151832)
9. Sahoo DH, Bandyopadhyay D, Xu M, et al. Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. Eur Respir J 2011; 38: 1145-1150.
10. Cremers JP, Drent M, Bast A, et al. Multinational evidence-based World Association of Sarcoidosis and Other Granulomatous Disorders recommendations for the use of methotrexate in sarcoidosis: integrating systematic literature research and expert opinion of sarcoidologists worldwide. Curr Opin Pulm Med 2013; 19: 545-561.
11. Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006; 174: 795-802. (Pubitemid 44511661)
12. Judson MA, Baughman RP, Costabel U, et al. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J 2008; 31: 1189-1196.
13. Russell E, Luk F, Manocha S, et al. Long term follow-up of infliximab efficacy in pulmonary and extra-pulmonary sarcoidosis refractory to conventional therapy. Semin Arthritis Rheum 2013; 43: 119-124.
14. Vorselaars ADM, Verwoerd A, van Moorsel CHM, et al. Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis. Eur Respir J 2014; 43: 602-609.
15. Liu Y, Wu EQ, Bensimon AG, et al. Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis. Adv Ther 2012; 29: 620-634.
16. Swider C, Schnittger L, Bogunia-Kubik K, et al. TNF-alpha and HLA-DR genotyping as potential prognostic markers in pulmonary sarcoidosis. Eur Cytokine Netw 1999; 10: 143-146. (Pubitemid 29332769)
17. Seitzer U, Swider C, Stüber F, et al. Tumour necrosis factor alpha promoter gene polymorphism in sarcoidosis. Cytokine 1997; 9: 787-790. (Pubitemid 27477724)
18. Wijnen PA, Nelemans PJ, Verschakelen JA, et al. The role of tumor necrosis factor alpha G-308A polymorphisms in the course of pulmonary sarcoidosis. Tissue Antigens 2010; 75: 262-268.
19. Mugnier B, Balandraud N, Darque A, et al. Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum 2003; 48: 1849-1852. (Pubitemid 36828679)
20. Zeng Z, Duan Z, Zhang T, et al. Association between tumor necrosis factor-alpha (TNF-α) promoter -308 G/A and response to TNF-α blockers in rheumatoid arthritis: a meta-analysis. Mod Rheumatol 2013; 23: 489-495.
21. Quanjer PH, Tammeling GJ, Cotes JE, et al. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J 1993; 6: Suppl. 16, 5-40.
22. Rothkrantz-Kos S, van Dieijen-Visser MP, Mulder PG, et al. Potential usefulness of inflammatory markers to monitor respiratory functional impairment in sarcoidosis. Clin Chem 2003; 49: 1510-1517. (Pubitemid 37011740)
23. Erckens RJ, Mostard RL, Wijnen PA, et al. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol 2012; 250: 713-720.
24. Hoitsma E, De Vries J, Drent M. The small fiber neuropathy screening list: construction and cross-validation in sarcoidosis. Respir Med 2011; 105: 95-100.
25. Hoitsma E, De Vries J, van Santen-Hoeufft M, et al. Impact of pain in a Dutch sarcoidosis patient population. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20: 33-39. (Pubitemid 36559732)
26. de Kleijn WP, De Vries J, Wijnen PA, et al. Minimal (clinically) important differences for the Fatigue Assessment Scale in sarcoidosis. Respir Med 2011; 105: 1388-1395.
27. Grutters JC, Sato H, Pantelidis P, et al. Increased frequency of the uncommon tumor necrosis factor -857T allele in British and Dutch patients with sarcoidosis. Am J Respir Crit Care Med 2002; 165: 1119-1124. (Pubitemid 34415821)
28. Marotte H, Miossec P. Biomarkers for prediction of TNFa blockers response in rheumatoid arthritis. Joint Bone Spine 2010; 77: 297-305.
29. Rossman MD, Newman LS, Baughman RP, et al. A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23: 201-208. (Pubitemid 47596315)
30. Croft AP, Situnayake D, Khair O, et al. Refractory multisystem sarcoidosis responding to infliximab therapy. Clin Rheumatol 2012; 31: 1013-1018.
31. Ulbricht KU, Stoll M, Bierwirth J, et al. Successful tumor necrosis factor alpha blockade treatment in therapyresistant sarcoidosis. Arthritis Rheum 2003; 48: 3542-3543. (Pubitemid 37531922)
32. Parambil JG, Tavee JO, Zhou L, et al. Efficacy of intravenous immunoglobulin for small fiber neuropathy associated with sarcoidosis. Respir Med 2011; 105: 101-105.
33. Beaugerie L, Sokol H. Clinical, serological and genetic predictors of inflammatory bowel disease course. World J Gastroenterol 2012; 18: 3806-3813.
34. D'Haens GR, Panaccione R, Higgins PD, et al. The London position statement of the world congress of gastroenterology on biological therapy for IBD with the European Crohn's and colitis organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 2011; 106: 199-212.
35. Winthrop KL, Baddley JW, Chen L, et al. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA 2013; 309: 887-895.
36. Grijalva CG, Chen L, Delzell E, et al. Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011; 306: 2331-2339.
37. Kestens C, van Oijen MG, Mulder CL, et al. Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-α agents. Clin Gastroenterol Hepatol 2013; 11: 826-831.
38. Fénix-Caballero S, Alegre-del Rey EJ, Castaño-Lara R, et al. Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis. J Clin Pharm Ther 2013; 38: 286-293.